HBM holdings partners with Pfizer for preclinical antibody discovery

HBM Holdings Limited, through its wholly-owned subsidiary Nona Biosciences, has entered into a non-exclusive license agreement with Pfizer. This agreement grants Pfizer global rights to access Nona Biosciences' proprietary HCAb platform for generating fully human heavy chain-only antibodies. The goal is to accelerate preclinical antibody discovery across various potential disease indications.

Under the terms, Nona Biosciences will receive an upfront payment from Pfizer. The company is also eligible to receive further payments upon the achievement of regulatory, clinical, and commercial milestones. The collaboration may involve Nona Biosciences working with Pfizer on antibody discovery, development, and engineering, utilizing its HCAb platform, advanced B-cell screening technologies, and integrated services.

HBM Holdings issued a cautionary statement, advising shareholders and potential investors to exercise due care when dealing in the company's shares. The company notes there is no guarantee that HBM Holdings or its collaboration partners will successfully develop or ultimately market the product candidates referenced in this announcement.